MCPP

mCPP produces dose-dependent mild elevations in blood pressure and heart rate, confirmed to be 5-HT2 receptor-mediated (attenuated by ritanserin). While no cardiovascular fatalities have been attributed specifically to mCPP, pre-existing cardiovascular conditions may be exacerbated.

mCPP activates 5-HT2 receptors present on bronchial smooth muscle, inducing bronchoconstriction. A 20-year-old male with pre-existing allergic asthma died from cardiorespiratory arrest after ingesting approximately 20 mg of mCPP. The mechanism involves serotonin-mediated airway constriction that can violently decompensate pre-existing reactive airways disease. This contraindication extends to patients receiving trazodone (which generates mCPP as a metabolite) who have asthma.

mCPP reliably induces panic-like states and acute anxiety in both healthy volunteers and psychiatric patients at clinical challenge doses (0.08-0.5 mg/kg). Individuals with pre-existing generalized anxiety disorder, panic disorder, or social anxiety disorder are at heightened risk of severe psychological distress.

mCPP significantly worsens obsessive-compulsive symptoms in OCD patients, as first documented by Zohar & Insel (1987). Lower doses (0.25 mg/kg) produce more OCD-specific symptom exacerbation, while higher doses are broadly anxiogenic. This is one of the most replicated findings in the mCPP challenge literature.

Individuals with borderline personality disorder experience heightened vulnerability to mCPP-induced psychological distress, including depersonalization and acute dysphoria. Simeon et al. documented depersonalization responses across multiple psychiatric populations including BPD.

Individuals with psychotic spectrum disorders may experience destabilization from mCPP's serotonergic effects. Direct evidence is limited, but the compound's reliably aversive psychological profile and depersonalization-inducing properties present elevated risk.

Co-administration of mCPP with monoamine oxidase inhibitors poses extreme serotonin syndrome risk. mCPP both releases serotonin via SERT substrate activity and directly activates 5-HT2C receptors; MAOIs prevent serotonin metabolism, creating potentially fatal serotonergic excess.

Concurrent use of SSRIs or SNRIs with mCPP raises serotonin syndrome risk through complementary mechanisms. SSRIs block serotonin reuptake while mCPP releases serotonin and directly activates 5-HT2C receptors. Several SSRIs (paroxetine, fluoxetine) additionally inhibit CYP2D6, elevating mCPP plasma concentrations pharmacokinetically.

Tramadol possesses serotonergic activity (weak SERT inhibitor/releaser) that combines with mCPP's 5-HT2C agonism and serotonin-releasing properties to elevate serotonin syndrome risk. No published fatal case of this specific combination was identified, but the mechanism is pharmacologically well-supported.

Triptans activate 5-HT1B/1D receptors; combined with mCPP's 5-HT2C agonism and serotonin-releasing activity, additive serotonergic load may precipitate serotonin syndrome.

Patients receiving trazodone, nefazodone, or etoperidone are already continuously exposed to mCPP as an active metabolite. Additional exogenous mCPP intake produces additive serotonergic effects and elevated total mCPP plasma concentrations.

CYP2D6 poor metabolizers (approximately 5-10% of Caucasian populations) achieve substantially higher mCPP plasma concentrations from any given dose due to impaired ring hydroxylation metabolism. The documented 8-fold variability in oral peak plasma levels means that doses perceived as 'light' by extensive metabolizers may produce 'strong' effects in poor metabolizers.